Hepatitis C
Conditions
Brief summary
Patients with hepatitis c showed increased level of oxidative stress. Increased level of serum lipid peroxidation leads to the production of toxic mediators as malondialdehyde (MDA) which lead to disease progression. Chronic stress shunt tryptophan which is essential amino acid toward kynurenic pathway leading to lower level of serotonin and melatonin level. Currently, direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV).
Interventions
hepatitis C patients will be treated by direct acting antiviral drugs (DAAs)for 12 weeks.
Sponsors
Tanta University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Inclusion criteria
* chronic hepatitis C patients had no other cause of liver disease
Exclusion criteria
* Patients with hepatitis B virus (HBV). * Patients with acute hepatitis. * Patients with renal insufficiency. * Patients with Hepatocellular carcinoma (HCC) or other types of malignancy. * Patients on current use of melatonin. * Patients using of any of medications that have interaction with melatonin. * Patients work in night shifts. * Patients are consuming a lot of caffeine or heavy smokers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in malondialdehyde (MDA) level. | 12 weeks following end of treatment. | Malondialdehyde (MDA) levels will be measured by the TBARS assay (thiobarbituric acid reactive substance assay) |
| Change in melatonin level. | 12 weeks following end of treatment. | Melatonin will be measured by using immunological method. |
Contacts
Primary ContactHeba M Hashem, Assistant lecturer
Backup ContactNageh A El-Mahdy, Professor
Outcome results
None listed